Skip to main content

Table 3 The relationship of mortality and initiation timing of HAART among HIV-TB co-infected patients*

From: The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study

 

Total (n = 218)

Death (N = 52, 24%)

Hazard ratio (95% CI)

Adjusted HR$(95% CI)

Adjusted HR#(95% CI)

Age at TB diagnosis (per 5-year increase)

  

1.14 (1.03-1.27)

1.12 (1.01-1.25)

1.13 (0.97-1.32)

CD4 count at TB diagnosis (per 50-cell increase)

  

0.94 (0.83-1.06)

0.81 (0.71-0.92)

0.79 (0.60-1.05)

IRIS

57

5 (8.8%)

0.26 (0.10-0.65)

0.36 (0.14-0.97)

0.36 (0.13-0.95)

HAART initiation timing during anti-TB therapy

  No HAART

36

23 (63.9%)

1

1

 

  0–15 days

110

19 (17.3%)

0.17 (0.09-0.31)

0.14 (0.07-0.27)

0.97 (0.34-2.70)

  16–30 days

34

5 (14.7%)

0.14 (0.05-0.36)

0.10 (0.04-0.28)

0.69 (0.19-2.49)

  31–60 days

19

0 (0%)

–

–

–

  >60 days

19

5 (26.3%)

0.25 (0.10-0.67)

0.14 (0.05-0.39)

1

  1. Abbreviations: HAART highly active antiretroviral therapy, IRIS Immune reconstitution inflammatory syndrome.
  2. *Only enrolled cases with available CD4+ lymphocyte count. HBV co-infection, HCV co-infection and TB location were analyzed initially but the p value was greater than 0.15 and was not included for multivariate analysis and not shown in the table.
  3. $ Adjusted for age at TB diagnosis, CD4 + lymphocyte count, IRIS and HAART initiation timing (use no HAART as reference).
  4. #Excluded cases who did not start HAART during TB treatment and adjusted for age at TB diagnosis, CD4+ lymphocyte count, IRIS and HAART initiation timing (use after 60 day as reference).